Zobrazeno 1 - 9
of 9
pro vyhledávání: '"35"'
Autor:
Mark Vermeulen, Esmeralda van der Helm, Jort Vellinga, Benoit Christophe Stephan Callendret, Marina Koning, Jan Serroyen, Maria Grazia Pau, Kerstin Wunderlich, Roland Zahn, Hanneke Schuitemaker, Dirk Spek, Adile Gecgel, Barbara Petronella Sanders, Jerome Custers, Marija Vujadinovic, Masha Stalknecht, Karin de Boer
Publikováno v:
Human gene therapy, 29(3), 337-351. Mary Ann Liebert Inc.
Genetic vaccines based on replication-incompetent adenoviral (AdV) vectors are currently in clinical development. Monovalent AdV vectors express one antigen from an expression cassette placed in most cases in the E1 region. For many vaccines, inclusi
Autor:
Mary-Ellen Davies, Paul M. Keller, Mark D. Yeager, Danilo R. Casimiro, Nancy M. Dougherty, Laura L. Franlin, John W. Shiver, Elayne C. Dell, Andrew J. Bett, Philip S. Bennett, Helen C. Perry, Fubao Wang, Miguel Aste-Amezaga, Joseph M. Antonello, Deepa K. Patel
Publikováno v:
Human gene therapy. 15(3)
Replication-defective recombinant adenoviruses (rAd) are used as vectors for vaccines as well as for gene therapy. To determine type-specific antibodies to adenovirus (Ad) serotypes 2, 5, 24, 34, and 35, we developed quantitative neutralization assay
Autor:
Qijun Qian, Chengliang Zhou, Changqing Su, Xiaoping He, Hong-Ping Wu, Xinyuan Liu, Linfang Li, Wu Mengchao, Jia Liu, Qi Zhang, Chunyan Yang
Publikováno v:
Human Gene Therapy. 22:283-292
Conditionally replicative adenoviruses (CRAds) are widely used for cancer biotherapy and show a significant growth-suppressing effect on many types of cancer. However, it was reported that breast cancer was highly resistant to the infection of tradit
Publikováno v:
Human Gene Therapy. 20:728-738
A major obstacle for the efficacy of cancer gene therapy is the need to transduce a high proportion of tumor cells with genes that directly or indirectly cause their death. During the formation of certain organs, cells compete among themselves to col
Autor:
Ronald W. Lindsey, Patricia Yotnda, Robert E. McAlhany, Elizabeth A. Olmsted-Davis, Zbigniew Gugala, Francis H. Gannon, Alan R. Davis
Publikováno v:
Human Gene Therapy. 13:1337-1347
Recombinant adenoviral vectors have potential for the treatment of a variety of musculoskeletal defects and such gene therapy systems have been a recent research focus in orthopedic surgery. In studies reported here, two different adenovirus vectors
Autor:
Eric J. Kremer, Miguel Chillón
Publikováno v:
Human Gene Therapy
Human Gene Therapy, Mary Ann Liebert, 2001, 12 (14), pp.1815--1823. ⟨10.1089/104303401750476302⟩
Human Gene Therapy, Mary Ann Liebert, 2001, 12 (14), pp.1815--1823. ⟨10.1089/104303401750476302⟩
Canine adenovirus type 2 (CAV-2) vectors may be attractive tools for gene transfer thanks to the lack of preexisting immunity in humans, and because of the preferential transduction of neurons when the vector is injected into the brain and some inner
Autor:
Andrea Gambotto, Hongjie Wang, Andy Baker, Ying Liu, Wentao Gao, André Lieber, Takashi Morita, Dmitry M. Shayakhmetov, Roma Yumul
Publikováno v:
Human gene therapy. 20(6)
Inefficient tumor transduction with targeted adenoviral vectors is largely due to unspecific virus sequestration by blood components, including coagulation factor X, and Kupffer cell scavenging. In this study, we show that preinjection of snake venom
Autor:
Josephine Nalbantoglu, Carol Allen, Jatinderpal R. Deol, Vinit Krishna Srivastava, George Karpati, Nancy Larochelle, Paul C. Holland, Hiroyuki Mizuguchi
Publikováno v:
Human gene therapy. 19(2)
Adenoviral vectors that use the coxsackievirus and adenovirus receptor do not transduce mature muscle efficiently. Group B adenoviruses use CD46 as their cell attachment receptor. To evaluate the utility of vectors based on group B adenoviruses for g
Publikováno v:
Human Gene Therapy. :061222090124001
The clinical course of sarcoma warrants the development of new therapeutic options, such as gene therapy. However, the lack of coxsackievirus-adenovirus receptor (CAR) on sarcoma cells limits the efficacy of adenovirus type 5 (Ad5)-based gene therapy